Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two doses of either the Pfizer or Oxford-AstraZeneca vaccine offer similar protection against symptomatic SARS-CoV-2 infection to that coming from natural immunity after infection, an ongoing study of healthcare workers has found.

OUH’s Chief Nurse, Sam Foster, delivers a Pfizer vaccine to a member of staff

None of the 1,456 healthcare workers at Oxford University Hospitals (OUH) NHS Foundation Trust who had received two vaccines had a symptomatic infection when followed up more than 14 days after their second vaccination. The same high level of protection was seen in unvaccinated healthcare workers who had contracted COVID-19 naturally; they had 98% fewer symptomatic infections than unvaccinated individuals who had not been infected before.

Most of the healthcare workers studied had only received one vaccine to date. Protection against symptomatic infection was lower – at 67% – after a first dose of vaccine – received by 11,023 hospital staff.

The findings were the latest data from ongoing analysis of symptomatic and asymptomatic staff testing for SARS-CoV-2 at OUH’s four hospitals and associated facilities. In total, 13,109 healthcare workers have participated.

Of these, 8,285 have received the Pfizer-BioNTech vaccine (1,407 of them two doses) and 2,738 the Oxford-AstraZeneca vaccine (49 of them receiving both doses).

Read the full story on the NIHR Oxford Biomedical Research Centre website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.